Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227 - Concepedia

Concepedia

Publication | Open Access

Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227

DOI Full Paper Access

142

Citations

16

References

2016

Year

Jon Glass, Minhee Won, Christopher J. Schultz, Daniel J. Brat, Nancy L. Bartlett, John H. Suh, Maria Werner‐Wasik, Barbara J. Fisher, Marcia K. Liepman, Mark E. Augspurger,

Journal of Clinical Oncology

Abstract

This regimen is safe, with the best 2-year OS and PFS achieved in any Radiation Therapy Oncology Group primary CNS lymphoma trial. Randomized trials that incorporate this regimen are needed to determine its efficacy compared with other strategies.

References

	Year	Citations

Page 1